Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.

Item
http://www.wikidata.org/entity/Q38475279
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the StoryEmerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimodMaternal inflammation activated ROS-p38 MAPK predisposes offspring to heart damages caused by isoproterenol via augmenting ROS generation.Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.New directions for pharmacotherapy in the treatment of acute coronary syndrome.LATITUDE-TIMI: is there still hope for anti-inflammatory therapy in acute myocardial infaction?Losmapimod does not reduce cardiovascular events in patients with acute myocardial infarction.Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.Fanning the flames: inflammation in cardiovascular diseases.
P2860

Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.

Item
http://www.wikidata.org/entity/Q38475279
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Rationale and design of the Lo ...... acute coronary syndromE trial.
@en
type
label
Rationale and design of the Lo ...... acute coronary syndromE trial.
@en
prefLabel
Rationale and design of the Lo ...... acute coronary syndromE trial.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Rationale and design of the Lo ...... acute coronary syndromE trial
@en
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698